“Alzheimer’s is open for business:” Controversial FDA approval could pave the way for future drugs,

The first, is a 17-year history of failure to bring a drug through clinical trials. Even Biogen’s clinical trials for Aduhelm were halted in 2019 because it wasn …, The first, is a 17-year history of failure to bring a drug through clinical trials. Even Biogen’s clinical trials for Aduhelm were halted in 2019 because it wasn …, Read More

Scroll to Top